Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061865 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02061865 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT02061865, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
Interventions
- DRUG REGN2176-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061865
The ClinicalTrials.gov registry entry for NCT02061865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REGN2176-3 is the first listed.
NCT02061865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02061865 about?
NCT02061865 is a clinical study titled "Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD". The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
What is the current status of trial NCT02061865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02061865?
The interventions under investigation include: REGN2176-3 (DRUG).
Who is sponsoring clinical trial NCT02061865?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.